140 related articles for article (PubMed ID: 38485187)
1. Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.
Mandal A; Shetty J; Tran CA; Olson WC; Mandal M; Ban B; Pires ES; Adair SJ; Bauer TW; Slingluff CL; Herr JC
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485187
[TBL] [Abstract][Full Text] [Related]
2. Oocyte specific oolemmal SAS1B involved in sperm binding through intra-acrosomal SLLP1 during fertilization.
Sachdev M; Mandal A; Mulders S; Digilio LC; Panneerdoss S; Suryavathi V; Pires E; Klotz KL; Hermens L; Herrero MB; Flickinger CJ; van Duin M; Herr JC
Dev Biol; 2012 Mar; 363(1):40-51. PubMed ID: 22206759
[TBL] [Abstract][Full Text] [Related]
3. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors.
Pires ES; D'Souza RS; Needham MA; Herr AK; Jazaeri AA; Li H; Stoler MH; Anderson-Knapp KL; Thomas T; Mandal A; Gougeon A; Flickinger CJ; Bruns DE; Pollok BA; Herr JC
Oncotarget; 2015 Oct; 6(30):30194-211. PubMed ID: 26327203
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.
Knapp KA; Pires ES; Adair SJ; Mandal A; Mills AM; Olson WC; Slingluff CL; Parsons JT; Bauer TW; Bullock TN; Herr JC
Oncotarget; 2018 Feb; 9(10):8972-8984. PubMed ID: 29507667
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody 7H2.2 binds the C-terminus of the cancer-oocyte antigen SAS1B through the hydrophilic face of a conserved amphipathic helix corresponding to one of only two regions predicted to be ordered.
Legg MSG; Gagnon SML; Powell CJ; Boulanger MJ; Li AJJ; Evans SV
Acta Crystallogr D Struct Biol; 2022 May; 78(Pt 5):623-632. PubMed ID: 35503210
[TBL] [Abstract][Full Text] [Related]
6. SAS1B protein [ovastacin] shows temporal and spatial restriction to oocytes in several eutherian orders and initiates translation at the primary to secondary follicle transition.
Pires ES; Hlavin C; Macnamara E; Ishola-Gbenla K; Doerwaldt C; Chamberlain C; Klotz K; Herr AK; Khole A; Chertihin O; Curnow E; Feldman SH; Mandal A; Shetty J; Flickinger C; Herr JC
Dev Dyn; 2013 Dec; 242(12):1405-26. PubMed ID: 24038607
[TBL] [Abstract][Full Text] [Related]
7. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers.
Qian J; Wang Q; Xiao L; Xiong W; Xian M; Su P; Yang M; Zhang C; Li Y; Zhong L; Ganguly S; Zu Y; Yi Q
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38267222
[TBL] [Abstract][Full Text] [Related]
8. The detection of SAS1B in serum provides clues for early diagnosis of thyroid cancer.
Yang HX; Yang Y; Li XD; Miao XM; Yang C; Zhi DF; Su H; Yang G; Gao J; Du CG; Li HJ; Song YL; Cao GF
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1410-1424. PubMed ID: 33629311
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
10. JUNO, the receptor of sperm IZUMO1, is expressed by the human oocyte and is essential for human fertilisation.
Jean C; Haghighirad F; Zhu Y; Chalbi M; Ziyyat A; Rubinstein E; Gourier C; Yip P; Wolf JP; Lee JE; Boucheix C; Barraud-Lange V
Hum Reprod; 2019 Jan; 34(1):118-126. PubMed ID: 30517645
[TBL] [Abstract][Full Text] [Related]
11. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
12. PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin.
Canals Hernaez D; Hughes MR; Dean P; Bergqvist P; Samudio I; Blixt O; Wiedemeyer K; Li Y; Bond C; Cruz E; Köbel M; Gilks B; Roskelley CD; McNagny KM
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243933
[TBL] [Abstract][Full Text] [Related]
13. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
[TBL] [Abstract][Full Text] [Related]
14. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers.
Garambois V; Glaussel F; Foulquier E; Ychou M; Pugnière M; Luo RX; Bezabeh B; Pèlegrin A
BMC Cancer; 2004 Oct; 4():75. PubMed ID: 15488142
[TBL] [Abstract][Full Text] [Related]
15. Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates.
Hebert C; Norris K; Sauk JJ
J Drug Target; 2003 Feb; 11(2):101-7. PubMed ID: 12881196
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibody-Drug Conjugate.
Cox EC; Thornlow DN; Jones MA; Fuller JL; Merritt JH; Paszek MJ; Alabi CA; DeLisa MP
Cancer Res; 2019 Apr; 79(8):1810-1821. PubMed ID: 30808675
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells.
Masuko K; Okazaki S; Satoh M; Tanaka G; Ikeda T; Torii R; Ueda E; Nakano T; Danbayashi M; Tsuruoka T; Ohno Y; Yagi H; Yabe N; Yoshida H; Tahara T; Kataoka S; Oshino T; Shindo T; Niwa S; Ishimoto T; Baba H; Hashimoto Y; Saya H; Masuko T
PLoS One; 2012; 7(1):e29728. PubMed ID: 22272243
[TBL] [Abstract][Full Text] [Related]
18. Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells.
Hellmann I; Waldmeier L; Bannwarth-Escher MC; Maslova K; Wolter FI; Grawunder U; Beerli RR
Front Immunol; 2018; 9():2490. PubMed ID: 30450096
[TBL] [Abstract][Full Text] [Related]
19. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
20. A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer.
Haji Ghaffari M; Simonian M; Salimi A; Mirzadegan E; Sadeghi N; Nejadmoghaddam MR; Ebrahimnezhad N; Fazli G; Fatemi R; Bayat AA; Mazloomi M; Rabbani H
Breast Cancer; 2022 Nov; 29(6):1121-1132. PubMed ID: 35982394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
